Skip to main content

Long-acting progestins — an update

Advances in Contraception volume 5, pages 241–251 (1989)Cite this article

This is a preview of subscription content, access via your institution.

References

  1. SnowdenR. (1985).Consumer Choice in Family Planning. Family Planning Association, London

    Google Scholar 

  2. MakepieceA.W., WeinsteinG.L. and FriedmanM.H. (1937). The effect of progestin and progesterone on ovulation in the rabbit.Am. J. Physiol.,119, 512–516

    Google Scholar 

  3. JunkmannK. and WitzelH. (1958). Chemistry and pharmacology of steroidal hormone esters.Z. Vitamin, Hormon, Fermentforsch.,9, 97–143

    Google Scholar 

  4. RinehartW. (1975). Minipill — A limited alternative for certain women. Population Reports, Series A, Number 3. Washington, DC. Population Information Program, pp. 16

    Google Scholar 

  5. DavisM.E. and WiedG.L. (1957). Long-acting progestational agents.Geburtsh. Frauenh.,17 (10), 916–928

    PubMed  Google Scholar 

  6. BabcockJ.C. et al. (1958). 6α-methyl-17α-hydroxy-progesterone-17-acylates: A new class of potent progestins.J. Am. Chem. Soc.,80, 2902–2905

    Google Scholar 

  7. BerlinerV.R. (1974). US Food and Drug Administration requirements for toxicity testing of contraceptive products.Acta Endocrinol.,75 (185), 240–265

    Google Scholar 

  8. HillR. et al. (1970). Progestational potency of chlormadinone acetate in the immature beagle bitch: preliminary report.Contraception,2 (6), 381–390

    Google Scholar 

  9. NelsonL.W. et al. (1972). Canine mammary neoplasms and progestogens.J. Am. Med. Assoc.,219 (12), 1601–1606

    Google Scholar 

  10. BenagianoG., DiczfalusyF., GoldzieherJ.W. and GrayR. (Co-ordinators WHO Task Force on Long-acting Systemic Agents for the Regulation of Fertility) (1977). Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: norethisterone enanthate and medroxy progesterone acetate 1. Use effectiveness.Contraception,15, 513–533

    PubMed  Google Scholar 

  11. Liskin, L.S. and Quillin, W.F. (1983). Long-acting progestins — promise and prospects.Pop. Rep., K (2), pp. 19–55

  12. International Planned Parenthood Federation (IPPF). International Medical Advisory Panel (1980) Injectable contraception.IPPF Med. Bull.,14 (6), 1–3

    Google Scholar 

  13. World Health Organisation (1982). Injectable hormonal contraceptives: technical and safety aspects. Geneva,WHO Offset Publication,65, 45

    Google Scholar 

  14. WeinerE. and JohanssonE.D.B. (1975). Plasma levels of norethindrone after intramuscular injection of 200 mg norethindrone enanthate.Contraception,11, 419–425

    PubMed  Google Scholar 

  15. Castaneda Leal, A. and Rios Castro, B. (1976). Clinical study of medroxy progesterone acetate in family planning programs. In:Contraceptive Progress in Latin America and the Caribbean, H. Sahueza and R. Jaimes, eds., Proceedings of the IPPF/WHR 2nd Regional Medical Seminar, Medellin, Colombia, New York, International Planned Parenthood Federation (IPPF), pp. 8–16

  16. Khanom, F. (1980). Injectable hormonal contraceptive in Mohammadput Fertility Services and Training Centre. In: Bangladesh Fertility Research Programme (BFRP). Workshop on Injectable Contraceptive (Noristerat), Dacca, Bangladesh, DACA, BFRP, pp. 113–116

  17. World Health Organisation (1978). Expanded Programme of Research, Development and Research Training in Human Reproduction. Task Force on Long-acting Systemic Agents for the Regulation of Fertility. Multinational comparative clinical evaluation of two long acting injectable contraceptive steroids: norethisterone oenanthate and medroxy progesterone acetate: 1. Bleeding patterns and side-effects.Contraception,17 (5), 395–406

    Google Scholar 

  18. SwensonI., KhanA.R. and JahanF.A. (1980). A randomized single blind comparative study of norethindrone enanthate and depo medroxy progesterone acetate in Bangladesh.Contraception,21 (3), 207–215

    PubMed  Google Scholar 

  19. World Health Organisation (1982). Special Programme of Research, Development, Research Training in Human Reproduction. Task Force on Long-acting Systemic Agents for the Regulation of Fertility. Multinational comparative clinical trial of long acting injectable contraceptives: norethisterone oenanthate given in two dosage regimens and depo medroxy progesterone acetate: A preliminary report.Contraception,25 (1), 1–11

    Google Scholar 

  20. Ad Hoc Consultative Panel on Depo Medroxy Progesterone Acetate (1980). Report to USAID of the Ad Hoc Consultative Panel of Depo Medroxy Progesterone Acetate, New York City, December 7–8, 1978, pp. 59

  21. GordonT., CastelliW.P., HjortlandM.C., KannelW.B. and DawberT.R. (1977). High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study.Am. J. Med.,62 (5), 707–714

    PubMed  Google Scholar 

  22. MillerN.E., FordeO.H., ThelleD.S. and MjosO.D. (1977). The Tromso Heart Study: High density lipoprotein and coronary heart disease: A prospective case control study.Lancet,1 (8019), 965–968

    PubMed  Google Scholar 

  23. FotherbyK., TraynerI., HowardG., HamawiA. and ElderM.G. (1982). Effect of injectable norethisterone oenanthate on blood lipid levels.Contraception,25 (4), 435–446

    PubMed  Google Scholar 

  24. FraserI.S. and WeisbergF. (1981). A comprehensive review of injectable contraception with special emphasis on depot medroxy progesterone acetate.Med. J. Aust.,1 (Special Suppl.), 1–19

    Google Scholar 

  25. KayC.R. (1982). Progestogens and arterial disease: evidence from the Royal College of General Practitioners' Study.Am. J. Obstet. Gynecol.,142 (6, Pt 2), 762–765

    PubMed  Google Scholar 

  26. Larosa, J.C. (1982). Testimony of John C. Larosa submitted to theUS FDA Public Board of Inquiry on Depo-Provera, FDA Docket No. 78 N-0124, pp. 25

  27. DhallK., KumarM., RastogiG.K. and DeviP.K. (1977). Short-term effects of norethisterone oenanthate and medroxy progesterone acetate on glucose, insulin, growth hormone, and lipids.Fertil. Steril.,28 (2), 156–158

    PubMed  Google Scholar 

  28. MukherjeeP., BuswasR., BanerjeeS.K. and MukherjeeM. (1977). Effect of depo-provera on the activity of some enzymes and lipid levels of human blood. In:Fourth Transaction of Scientific Papers at the India FRP Contributor's Conference, Bombay, Feb 24, 1977, S.Pachauri, ed., Calcutta, India Fertility Research Programme, pp. 225–230

    Google Scholar 

  29. TankeyoonM., DusitsinN., PoshyachindaV. and Larsson-CohonU. (1976). A study of glucose tolerance, serum transaminase and lipids in women using depot medroxy progesterone acetate and a combination-type oral contraceptive.Contraception,14 (2), 199–214

    PubMed  Google Scholar 

  30. World Health Organisation (1982). Facts about injectable contraceptives.Bull. WHO,60 (2), 199–210

    Google Scholar 

  31. United States Food and Drug Administration (US FDA) (1978). Obstetrics and Gynecology Device Classification Panel and US FDA Obstetrics and Gynecology Drug Advisory Committee.Second Report on Intrauterine Contraceptive Devices, Washington DC, Government Printing Office, December 1978, p. 102

    Google Scholar 

  32. IsaacsW.A., EffiongC.E. and AyeniO. (1972). Steroid treatment in the prevention of painful episodes in sickle-cell disease.Lancet,1 (7750), 570–571

    PubMed  Google Scholar 

  33. SchwallieP.C. and AssenzoJ.R. (1974). Contraceptive use efficacy study utilizing medroxy progesterone acetate administered as an intramuscular injection once every 90 days.Fertil. Steril.,24 (5), 331–339

    Google Scholar 

  34. Crabbe, P., Arcjer, S., Benangiano, G. Diczfalusy, E., Djersassi, C., Fried, J. and Higuchi, T. (1989). Long acting contraceptive agents: design of the WHO Chemical Synthesis Programme.Steroids (Suppl.) (In press)

  35. PremaK., GayathiriT.L., RamalakshmiB.A., MadhavapeddiR. and PhilipsF.S. (1981). Low dose injectable contraceptive norethisterone enanthate 20 mg monthly. I. Clinical trials.Contraception,23, 11–22

    PubMed  Google Scholar 

  36. PrasadK.V.S., NairK.M., SivakumarB., PremaK. and RaoB.S.N. (1981). Plasma levels of norethindrone in Indian women receiving norethindrone enanthate (20 mg) injectable.Contraception,23, 497–506

    PubMed  Google Scholar 

  37. HallP.E. (1987). Long acting injectable formulations. In:Fertility Regulation, Today and Tomorrow, E.Diczfalusy and M.Bygdeman, eds., Raven Press, New York, pp. 119–141

    Google Scholar 

  38. World Health Organisation (1987a). Task force on long acting systemic agents for fertility regulation: A multicentered pharmacokinetics, pharmacodynamic study of once-a-month injectable contraceptives: I. Different doses of HRP 112 and Depo-Provera.Contraception,36, 441–457

    Google Scholar 

  39. SivinI. and BrownG.F. (1983). The introduction of Norplant implants.Stud. Fam. Plann.,14, 192–193

    PubMed  Google Scholar 

  40. KlitschM. (1983). Hormonal implants: The new waves of contraceptives.Int. Fam. Plann. Perspect.,9 (4), 119–122

    Google Scholar 

  41. World Health Organisation (1985). Facts about an implantable contraceptive.Bull. WHO,63 (3), 485–494

    Google Scholar 

  42. SivinI. et al. (1983). A four-year clinical study of Norplant implants.Stud. Fam. Plann.,14, 184–191

    PubMed  Google Scholar 

  43. ShaabanM.M. et al. (1983). A prospective study of Norplant implants and the TCu 380 Ag. IUD in Assiut, Egypt.Stud. Fam. Plann.,14, 163–169

    PubMed  Google Scholar 

  44. SatayapanS. et al. (1983). Perceptions and acceptability of Norplant implants in Thailand.Stud. Fam. Plann.,14, 170–176

    PubMed  Google Scholar 

  45. MarangoniP. et al. (1983). Norplant implants and the TCu 200 IUD: A comparative study in Ecuador.Stud. Fam. Plann.,14, 177–180

    PubMed  Google Scholar 

  46. LubisF. et al. (1983). One-year experience with Norplant implants in Indonesia.Stud. Fam. Plann.,14, 181–183

    PubMed  Google Scholar 

  47. SinghK., ViegasO. and RatnamS.S. (1989). Norplant contraceptive subdermal implants — two year experience in Singapore.Adv. Contracept.,5, 13–22

    PubMed  Google Scholar 

  48. CroxattoH.B. et al. (1983). Clinical chemistry in women treated with levonorgestrel implants or a TCu 200 IUD.Contraception,27, 281–288

    PubMed  Google Scholar 

  49. ShaabanM.M. et al. (1984). Effect of subdermal levonorgestrel contraceptive implants (Norplant) on serum lipids.Contraception,30, 413–419

    PubMed  Google Scholar 

  50. RobertsonD.N. (1983). Norgestrel-releasing Silastic rods: Clinical effects, biochemical effects and in vivo release rates. In:Advances in Human Fertility and Reproductive Endocrinology, Vol. 2: Long Acting Steroid Contraception. D.R.MishellJr., ed., Raven Press, New York, pp. 127–147

    Google Scholar 

  51. SinghK., ViegasO., LiewD., SinghP. and RatnamS.S. (1989). Two year follow-up of changes in clinical chemistry in Singaporean Norplant acceptors: Metabolic changes.Contraception,39 (2), 129–136

    PubMed  Google Scholar 

  52. SinghK., ViegasO., LiewD., SinghP. and RatnamS.S. (1989). Two year follow-up of changes in clinical chemistry in Singaporean Norplant-2 rod acceptors: Metabolic changes.Contraception,39 (2), 147–154

    PubMed  Google Scholar 

  53. SinghK., ViegasO., SinghP. and RatnamS.S. (1988). Norplant contraceptive subdermal implant: one year experience in Singapore.Contraception,37 (5), 457–469

    PubMed  Google Scholar 

  54. SinghK., ViegasO. and RatnamS.S. (1988). Norplant-2 rods: A one year experience in Singapore.Contraception,38 (4), 429–440

    PubMed  Google Scholar 

  55. World Health Organisation (1980). Special Programme of Research, Development and Research Training in Human Reproduction. Ninth annual report. WHO Geneva, p. 162

    Google Scholar 

  56. World Health Organisation Task Force on Long-acting Systemic Agents for Fertility Regulation (1988). Pharmacokinetic profiles and pharmacodynamic effects of capronor contraceptives implants in the human.Contraception, (in press)

  57. NashH.A. and JackaniczT.M. (1982). Contraceptive vaginal rings. In:Advances in Fertility Research, Vol, 1, D.R.MishellJr., ed., Raven Press, New York, pp. 129–144

    Google Scholar 

  58. DiczfalusyE. (1986). New developments in oral, injectable and implantable contraceptives, vaginal rings and intrauterine devices. A review.Contraception,33 (1), 7–22.

    PubMed  Google Scholar 

  59. SivinI., MishellD.P.Jr., VictorA., DiazS., Alvarez-SanchezF., NielsenN.C., AkinlaO., PyoralaT., CoutinhoE., FaundesA., RoyS., BrennerP.F., AhrenT., PavezM., BracheV., Giwa-OsagieO.F., FasanM.O., Zausner-GuelmanB., DarzeE., SilvaJ.C.G.Da., DiazJ., JackaniczT.M., SternJ. and NashN.A. (1981). A multicenter study of levonorgestrel oestradiol contraceptive vaginal rings, 1. Use effectiveness: an international comparative trial.Contraception,24 (4), 341–358

    PubMed  Google Scholar 

  60. SivinI., MishellD.P.Jr., VictorA., DiazS., Alvarez-SanchezF., NielsenN.C., AkinlaO., PyoralaT., CoutinhoE., FaundesA., RoyS., BrennerP.F., AhrenT., PavezM., BracheV., Giwa-OsagieO.F., FasanM.O., Zausner-GuelmanB., DarzeE., DaSilvaJ.C.G., DiazJ., JackaniczT.M., SternJ., and NashN.A. (1981). A multicentre study of levonorgestrel oestradiol contraceptive vaginal rings. 2. Subjective and objective measures of effects: An international comparative trial.Contraception,24 (4), 359–376

    PubMed  Google Scholar 

  61. World Health Organisation (1978). Special Programme of Research, Development and Research Training in Human Reproduction. Seventh annual report, Geneva, WHO, p. 167

    Google Scholar 

  62. Diczfalusy, E. and Landgren, B.M. (1981). New developing systems: vaginal devices. In:Recent Advances in Fertility Regulation, C.F. Chang, D. Griffin and A. Woolman, eds. Proceedings of a symposium organized by the Ministry of Public Health of the People's Republic of China, and the World Health Organisations' special programme of research, development and research training in human reproduction, Beijing, September 2–5, 1980, Geneva, Atar, pp. 43–69

  63. RoweP.J. (1984). Steroid-releasing vaginal rings: A review. In:Fertility and Sterility, R.F.Harrison, J.Bonnar and W.Thompson, eds., MTP Press Ltd, Lancaster, pp. 301–309

    Google Scholar 

  64. LandgrenB.M. (1987). Vaginal delivery systems. In:Fertility Regulation, Today and Tomorrow, E.Diczfalusy and M.Bygdeman, eds., Raven Press, New York, pp. 165–180

    Google Scholar 

  65. BeckL.R., CowsarD.R. and PopeV.Z. (1980). Long-acting steroidal contraceptive systems.Res. Front. Fertil. Regul.,1 (1), 1–16

    Google Scholar 

  66. Alza Corporation (1976). The Progestasert: intrauterine progesterone contraceptive system: release rated 65 μg/day progesterone for one year. Palo Alto, California, Alza Corporation, p. 61

    Google Scholar 

  67. World Health Organisation special Programme of Research, Development and Research Training in Human Reproduction: Task Force on Intrauterine Devices for Fertility Regulation (1987). Microdose intrauterine levonorgestrel for contraception, 35, pp. 363–379

  68. SivinI. and SchmidtF. (1987). Effectiveness of IUDs: A review.Contraception,3(1), 55–84

    Google Scholar 

Download references

Author information

Affiliations

  1. Department of Obstetrics and Gynaecology, National University of Singapore, 0511, Singapore

    K. Singh, O. A. C. Viegas & S. S. Ratnam

Authors
  1. K. Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. A. C. Viegas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. S. Ratnam
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Singh, K., Viegas, O.A.C. & Ratnam, S.S. Long-acting progestins — an update. Adv Contracept 5, 241–251 (1989). https://doi.org/10.1007/BF01890897

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01890897